EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Smaller infarct size with ticagrelor vs. clopidogrel in STEMI patients: Insights from cardiac magnetic resonance

Francisco A Fonseca iD, Adriano Caixeta, Gilberto Szarf, Ibraim Pinto, Antonio M Figueiredo Neto iD, Carolina N França, Henrique T Bianco iD, Henrique A Fonseca, Amanda S Bacchin, Michelle Birtche, Igor R M Batista iD, Maria C Izar iD und 1 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0328114 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Francisco A Fonseca und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, Universidade Federal de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: ST Elevation Myocardial Infarction, Platelet Aggregation Inhibitors, Adenosine, Ticlopidine. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FAPESP, AstraZeneca, INCT /CNPq.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ticagrelor has many protective cardiovascular properties beyond potent antiplatelet action. This study aimed to compare the effects of ticagrelor versus clopidogrel on infarcted mass, quantified by cardiac magnetic resonance (CMR), in patients with ST-segment elevation acute myocardial infarction (STEMI).

Methods

Adult patients of both sexes with STEMI under a pharmaco-invasive strategy were included (n = 225). Patients were treated by thrombolysis within six hours of symptom onset and underwent angiography with percutaneous coronary interventions, when needed, within the first 24 hours. Prior to the invasive procedures, patients were randomly assigned to receive either ticagrelor or clopidogrel using a centralized computerized system. Patients were followed on a weekly basis to optimize their medical therapy.

Results

After 30 days, CMR was performed and a smaller percentage of left ventricular infarcted mass was found with ticagrelor (p = 0.012), despite similar angiographic findings at baseline (Syntax score, Gensini score, culprit artery, TIMI flow, and myocardial blush). At 30 days, left ventricular ejection fraction (LVEF) was comparable between groups. Still, the K-means algorithm displayed more homogeneous responses for smaller infarcted mass and better LVEF among those patients treated with ticagrelor. Standard lipid panel and most inflammatory parameters were similar at baseline and after 30 days. However, lower high-sensitivity troponin T and high-sensitivity C-reactive protein levels were found in samples collected from patients treated with ticagrelor on the first day of STEMI.

Conclusion

In patients with STEMI under a pharmaco-invasive strategy, therapy with ticagrelor was associated with a smaller infarct size than clopidogrel.

Trial registration

Clinicaltrials.gov ( NCT02428374 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ST Elevation Myocardial InfarctionPlatelet Aggregation InhibitorsAdenosineTiclopidineHumansTicagrelorClopidogrelMaleFemaleMiddle AgedAgedMagnetic Resonance ImagingPercutaneous Coronary Intervention

Substanzen

TicagrelorClopidogrelPlatelet Aggregation InhibitorsAdenosineTiclopidine

Autor:innen und Institutionen

  • Cardiology Division, Universidade Federal de São Paulo, São Paulo, Brazil.
  • Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
  • Instituto de Física, Universidade São Paulo, São Paulo, Brazil.
  • Universidade Santo Amaro, São Paulo, Brazil.
  • Brazilian Network of Collaboration and Knowledge Advancement on Severe Hypertriglyceridemia - Hypertri Brazil Network, Casa Dos Raros, Porto Alegre, Brazil.

ORCID-Profile: Francisco A Fonseca, Antonio M Figueiredo Neto, Henrique T Bianco, Igor R M Batista, Maria C Izar

Förderung

  • FAPESP
  • AstraZeneca
  • INCT /CNPq
  • INCT/FAPESP
  • INCT/CAPES
  • INCT-FCx

Zitieren

APA

Fonseca, F. A., Caixeta, A., Szarf, G., Pinto, I., Figueiredo Neto, A. M., França, C. N., Bianco, H. T., Fonseca, H. A., Bacchin, A. S., Birtche, M., Batista, I. R. M., Izar, M. C., & BATTLE-AMI investigators (2025). Smaller infarct size with ticagrelor vs. clopidogrel in STEMI patients: Insights from cardiac magnetic resonance. PLOS One. https://doi.org/10.1371/journal.pone.0328114

Vancouver

Fonseca FA, Caixeta A, Szarf G, Pinto I, Figueiredo Neto AM, França CN, et al. Smaller infarct size with ticagrelor vs. clopidogrel in STEMI patients: Insights from cardiac magnetic resonance. PLOS One. 2025. doi:10.1371/journal.pone.0328114

BibTeX
@article{Fonseca2025,
  author = {Fonseca, Francisco A and Caixeta, Adriano and Szarf, Gilberto and Pinto, Ibraim and Figueiredo Neto, Antonio M and França, Carolina N and Bianco, Henrique T and Fonseca, Henrique A and Bacchin, Amanda S and Birtche, Michelle and Batista, Igor R M and Izar, Maria C and BATTLE-AMI investigators, BATTLE-AMI investigators},
  title = {Smaller infarct size with ticagrelor vs. clopidogrel in STEMI patients: Insights from cardiac magnetic resonance},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0328114}
}
Kostenlos starten →